Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ascorbic Acid for Vasoplegia in Cardiac Surgery
NCT03744702Phase 1Completed
- Sponsor
- Mayo Clinic
- Start
- Jun 2019
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ascorbic acid in Vasoplegia, sponsored by Mayo Clinic. Primary endpoints: Vasopressor duration in hours up to 10 days and Vasopressor dose up to 10 days. Started Jun 2019; status: completed.
02
Drugs
ascorbic acid
03
Conditions
Vasoplegia
Beyond the preview
Go deeper on NCT03744702.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03744702.